Medpace Holdings (MEDP) Cost of Revenue (2015 - 2026)

Medpace Holdings (MEDP) has 12 years of Cost of Revenue data on file, last reported at $505.7 million in Q2 2026.

• Quarterly Cost of Revenue rose 19.47% year-over-year to $505.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.0 billion (up 29.88% YoY) and the FY2025 annual result came in at $1.8 billion, up 21.81% from the prior year.
• Cost of Revenue retreated to $505.7 million in Q2 2026, from $510.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $510.3 million in Q1 2026 to a low of $232.3 million in Q1 2022.
• A 5-year average of $368.2 million and a median of $360.5 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue declined 0.92% — and 2025, when it jumped 40.43%.
• Tracing MEDP's Cost of Revenue over 5 years: stood at $278.4 million in 2022, then advanced by 29.9% to $361.6 million in 2023, then dropped by 0.92% to $358.3 million in 2024, then jumped by 40.43% to $503.1 million in 2025, then rose by 0.51% to $505.7 million in 2026.
• The last three Cost of Revenue figures came in at $505.7 million (Q2 2026), $510.3 million (Q1 2026), and $503.1 million (Q4 2025), per Business Quant data.